The Hyderabad-based pharmaceutical company Biological E Ltd on Monday received an emergency use approval from Drugs Controller General of India (DCGI) in India for use in children aged 12 to 18 years for its coronavirus vaccine Corbevax.
Corbevax is a “recombinant protein sub-unit” vaccine, developed from a component of the spike protein on the virus’s surface, which helps the body build the immune response against the virus.
The vaccine has the Receptor Binding Domain (RBD) protein as an antigen, and also an optimum adjuvant consisting of Dynavax (DVAX) CpG 1018 and alum
Corbevax is accorded emergency use authorization as a COVID-19 vaccine and is available for consumption only in India via authorized channels
The vaccine will be administered in two doses, according to reports. A leading news agency quoting official sources had reported that the expected cost of the vaccine is Rs 145 excluding taxes.
